U.S. Stock Market After-Hours Opening Movements

UnitedHealth rose 7.72% in after-hours trading. Based on recent news,

1. On April 6, the U.S. federal Medicare program announced it would pay private insurance companies 2.48% more in 2027, a significant improvement over the proposal in January. This news boosted the stock prices of companies like UnitedHealth, with UnitedHealth's after-hours increase reaching 9.9%.

2. On April 6, the Centers for Medicare & Medicaid Services (CMS) announced that the government would increase the average payment amount for the federal Medicare Advantage program by 2.48% in 2027, adding over $13 billion in scale. This news drove up UnitedHealth's stock price.

3. On April 6, analyst Raymond James upgraded UnitedHealth's rating from "Market Perform" to "Outperform," setting a target price of $330, citing more room for savings in general and administrative expenses, and improved visibility in the profitability of the Optum Health division. Policy adjustments in the Medicare industry boosted stock prices.

Elevance Health rose 7.07% in after-hours trading. Based on recent key news:

1. On April 7, Elevance Health formed a strategic partnership with 3Strands Global Foundation. This collaboration aims to provide comprehensive support for foster care programs in Virginia through Anthem Blue Cross and Blue Shield, enhancing market confidence in the company's future development and driving up stock prices.

2. On April 7, MN's Blue Cross and Blue Shield announced its financial data for 2025. Although specific details were not provided, the market held an optimistic view of the overall performance of the industry, further supporting Elevance Health's stock price increase. Industry collaboration strengthened market confidence, driving stock prices up.

Top Gainers in U.S. After-Hours Trading

Organogenesis rose 19.20% in after-hours trading. Based on recent key news:

1. On April 6, Organogenesis announced that its PuraPly®AM achieved its primary endpoint in a randomized controlled trial, showing significant effects in treating non-healing diabetic foot ulcers. This result strengthened the clinical evidence base for PuraPly, supporting its inclusion in future insurance policies and driving up stock prices.

2. On April 6, Organogenesis successfully completed a meeting with the U.S. Food and Drug Administration and plans to initiate a rolling Biologics License Application for ReNu® knee osteoarthritis pain. This move paves the way for the company to submit a BLA by the end of 2025, and the market reacted positively, leading to a rise in stock prices On April 6, the company announced that it will release its Q1 2026 financial report on May 7. Investors are optimistic about the upcoming financial data, further driving up the stock price. The biopharmaceutical industry has been active recently, with significant policy support.

Alignment Healthcare rose 15.85% in after-hours trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

iRobot rose 14.69% in after-hours trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation